Salience network (SN), playing a vital role in advanced cognitive function, is regarded to be impaired in subjective cognitive decline (SCD) and amnestic mild cognitive impairment (aMCI). The purpose of the study was to explore the importance of structural and functional features of SN in the diagnosis of SCD and aMCI. Structural and resting-state functional magnetic resonance imaging were collected from SCD, aMCI, and healthy control (HC). Cortex thickness, gray matter (GM) volume, spontaneous brain activity, functional connectivity (FC) within SN, and its relationship with cognitive function were analyzed. Moreover, the receiver operating characteristic analysis was performed to assess diagnostic efficacy of altered indictors for SCD and aMCI. Compared to HC, both SCD and aMCI showed decreased GM volume, decreased spontaneous brain activity, and increased FC within SN, while aMCI showed additional decreased cortex thickness. Furthermore, the altered FC in SCD and aMCI was significantly correlated with cognitive function. Particularly, the best-fitting classification models of SCD and aMCI were based on the combined multiple indicators. In conclusion, structure and function of SN were disrupted in SCD and aMCI, which involved in cognitive decline. The combined multiple indicators of SN provided powerful biomarkers for the diagnosis of SCD and aMCI.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acschemneuro.1c00051 | DOI Listing |
Digit Health
November 2024
Internal Medicine Department, Bucharest University Emergency Hospital, Bucharest, Romania.
Background: Research shows that older adults' performance on choice reaction time (CRT) tests can predict cognitive decline. A simple CRT tool could help detect mild cognitive impairment (MCI) and preclinical dementia, allowing for further stratification of cognitive disorders on-site or via telemedicine.
Objective: The primary objective was to develop a CRT testing device and protocol to differentiate between two cognitive impairment categories: (a) subjective cognitive decline (SCD) and non-amnestic mild cognitive impairment (na-MCI), and (b) amnestic mild cognitive impairment (a-MCI) and multiple-domain a-MCI (a-MCI-MD).
J Alzheimers Dis
November 2024
Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.
Front Aging Neurosci
October 2024
Digital Health Research Division, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea.
Background: This study utilized recent advancements in electroencephalography (EEG) technology that enable the measurement of prefrontal event-related potentials (ERPs) to facilitate the early detection of mild cognitive impairment (MCI). We investigated two-channel prefrontal ERP signals obtained from a large cohort of elderly participants and compare among cognitively normal (CN), subjective cognitive decline (SCD), amnestic MCI (aMCI), and nonamnestic MCI (naMCI) groups.
Methods: Signal processing and ERP component analyses, specifically adapted for two-channel prefrontal ERP signals evoked by the auditory oddball task, were performed on a total of 1,754 elderly participants.
Wien Klin Wochenschr
September 2024
Department of Neurology, Medical University of Vienna, Währinger Gürtel 18-20, 1097, Vienna, Austria.
Background: Thyroid hormones may affect olfaction in different stages of cognitive impairment: subjective cognitive decline (SCD), non-amnestic (naMCI) and amnestic mild cognitive impairment (aMCI). Additionally, biometric parameters, depression, and neuropsychological performance are considered as possible influencing factors.
Design And Patients: A retrospective single-center data analysis was conducted during the observation period 2001-2023, with n = 495 (52.
Alzheimers Res Ther
September 2024
Memory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic.
Background: There is initial evidence suggesting that biomarker neurogranin (Ng) may distinguish Alzheimer's disease (AD) from other neurodegenerative diseases. Therefore, we assessed (a) the discriminant ability of cerebrospinal fluid (CSF) Ng levels to distinguish between AD and frontotemporal lobar degeneration (FTLD) pathology and between different stages within the same disease, (b) the relationship between Ng levels and cognitive performance in both AD and FTLD pathology, and (c) whether CSF Ng levels vary by apolipoprotein E (APOE) polymorphism in the AD continuum.
Methods: Participants with subjective cognitive decline (SCD) (n = 33), amnestic mild cognitive impairment (aMCI) due to AD (n = 109), AD dementia (n = 67), MCI due to FTLD (n = 25), and FTLD dementia (n = 29) were recruited from the Czech Brain Aging Study.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!